An Assessment of Recent Changes in Drug Use and Drug Policies in The
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A Policy Perspective on the Global Use of Smokeless Tobacco
Curr Addict Rep DOI 10.1007/s40429-017-0166-7 TOBACCO (AH WEINBERGER, SECTION EDITOR) A Policy Perspective on the Global Use of Smokeless Tobacco Kamran Siddiqi1 & Aishwarya Lakshmi Vidyasagaran1 & Anne Readshaw1 & Ray Croucher2 # The Author(s) 2017. This article is an open access publication Abstract Keywords Smokeless tobacco . Snus . Tobacco control . Background Globally, over 300 million people consume di- Global health verse smokeless tobacco (ST) products. They are addictive, cause cancer, increased cardiovascular mortality risks and poor pregnancy outcomes. Introduction Purpose of Review To identify gaps in implementing key ST demand-reduction measures, focused literature reviews were “Smokeless tobacco” (ST) comprises tobacco products that do conducted and findings synthesized according to relevant not involve a combustion process, such as chewing, nasal and WHO Framework Convention on Tobacco Control (FCTC) oral tobacco [1•]. Globally, over 300 million people consume Articles. ST [1•], yet ST has been largely neglected in research and Recent Findings The literature supports implementation of policy arenas because it is generally regarded as less harmful ST demand-reduction measures. For taxation, labelling and than cigarettes. It is also seen as a regional rather than a global packaging, most administrations have weaker policies for ST problem, and too diverse and complex to control. than cigarettes. Capacity to regulate ST contents and offer ST use is reported in at least 116 countries worldwide, cessation support is lacking. There is poor compliance with including countries in Africa, Asia, Europe and the bans on ST advertising, promotion and sponsorship. Americas [2•]. Smokeless tobacco consumption is therefore Summary The literature on implementation of WHO a global public health issue. -
Mitty Does Les Misérables by Hannah Moeller Feat Was Even Possible
The Monarch Volume 18 Number 4 • Serving the Archbishop Mitty Community • April 2009 Members from the cast of Les Misérables after the show. All shows were sold out before opening night and a Saturday matinee had to be added. Success on the Stage: Mitty does Les Misérables By Hannah Moeller feat was even possible. To fully assess what was possible, and who could make it Staff Writer happen, he turned to Mr. Fairley, the faculty moderator of the Mitty Robotics Club. During the last few weeks of preparation for Mitty’s spring musical Les Misera- Mr. Fairley asked Robotics President junior Lucas Bolster and Stage Manager bles the Performing Arts Wing was a hidden world of intricately winding hallways and senior Carol Friedenbach to do the job, since both have strong backgrounds in robotics scattered rooms, all full of laughter, music, and excited chatter. Mitty’s performances and theater set technologies. For about a year, Mr. Fairley, Bolster, and Friedenbach of the Broadway hit ran for two weekends—the last weekend of March and the fi rst met every few weeks. They researched, designed, and constructed aspects of the of April. Les Mis tells the story of an ex-convict that is hunted by a law-obsessed revolving stage in order to make this complex set a success. ofi cer, all while the students of Paris revolt in 1830s France. “It was a lot of math,” said Friedenbach. “The revolve was built to go on top The Performing Arts Department decided during the second semester of last of the stage and extended outward. -
Executive Branch
EXECUTIVE BRANCH THE PRESIDENT BARACK H. OBAMA, Senator from Illinois and 44th President of the United States; born in Honolulu, Hawaii, August 4, 1961; received a B.A. in 1983 from Columbia University, New York City; worked as a community organizer in Chicago, IL; studied law at Harvard University, where he became the first African American president of the Harvard Law Review, and received a J.D. in 1991; practiced law in Chicago, IL; lecturer on constitutional law, University of Chicago; member, Illinois State Senate, 1997–2004; elected as a Democrat to the U.S. Senate in 2004; and served from January 3, 2005, to November 16, 2008, when he resigned from office, having been elected President; family: married to Michelle; two children: Malia and Sasha; elected as President of the United States on November 4, 2008, and took the oath of office on January 20, 2009. EXECUTIVE OFFICE OF THE PRESIDENT 1600 Pennsylvania Avenue, NW., 20500 Eisenhower Executive Office Building (EEOB), 17th Street and Pennsylvania Avenue, NW., 20500, phone (202) 456–1414, http://www.whitehouse.gov The President of the United States.—Barack H. Obama. Special Assistant to the President and Personal Aide to the President.— Anita Decker Breckenridge. Director of Oval Office Operations.—Brian Mosteller. OFFICE OF THE VICE PRESIDENT phone (202) 456–1414 The Vice President.—Joseph R. Biden, Jr. Assistant to the President and Chief of Staff to the Vice President.—Bruce Reed, EEOB, room 276, 456–9000. Deputy Assistant to the President and Chief of Staff to Dr. Jill Biden.—Sheila Nix, EEOB, room 200, 456–7458. -
Public Housing in a Competitive Market
_________________________________________________________________ PUBLIC HOUSING IN A COMPETITIVE MARKET: An Example of How It Would Fare _________________________________________________________________ April, 1996 U.S. Department of Housing and Urban Development Office of Policy Development and Research Division of Policy Studies FOREWORD During the last several years, a bipartisan consensus has emerged around the twin goals of significantly reducing the Federal deficit and substantially deregulating the Nation’s public housing system. Together, these changes in the Federal policy environment require public housing authorities to dramatically rethink their operating and management practices. With operating and capital dollars shrinking, optimizing the use of these resources will become increasingly important. This report, originally conceived to inform the Administrations’ proposal to replace the present system of public housing subsidies with portable, tenant-based assistance, provides housing authorities with a solid framework for making more strategic asset management and operating decisions. The report examines the local and Federal impacts of changing public housing in a major city -- Baltimore, Maryland -- to a tenant-assisted, market-based system. It attempts to model program outcomes in an environment in which most Federal regulations would be eliminated and operating subsidies terminated. It assumes current public housing residents in Baltimore would receive a fully-funded housing certificate/voucher that would enable them to -
HHS Presidential Transition Agency Landing Team Book
sERvick.s. 41- .41 c'o 4ifaa U.S. Department of Health & Human Services HHS Presidential Transition Agency Landing Team Book HHS Presidential Transition Team HHS - 200 Independence Avenue SW - Washington, DC 20201 WELCOME Message from the 2016 HHS Presidential Transition Team: Welcome to the Department of Health and Human Services (HHS). We are pleased to provide you with the 2016 HHS Presidential Transition briefing book for the Landing Team. This document is being distributed in both hard and soft copy to each member of the President-elect's Transition Team assigned to HHS. To maintain its purpose as a briefing document, the volume is not and was not intended to be all inclusive. In developing these materials, we reviewed prior Presidential Transition documents, interviewed individuals who led or participated in past Transitions, partnered with the Partnership for Public Service, and exchanged ideas through the Agency Transition Director's Council. Based on the lessons learned from past HHS Transitions and best practices gleaned from our government-wide teaming, we designed this package as follows: • The documents were prepared by senior career officials within HHS prior to the outcome of the election being known. • The book provides a comprehensive overview of NHS, but is not intended to provide every fact and figure. Instead, we have crafted a concise summary of major Departmental functions, activities, and processes to provide an overview which will assist you in gathering additional material about programs and processes of particular interest. • The briefing book includes key issues related to issues likely to come before the new Secretary within the first 30, 60, 90 days after the inauguration. -
Acting 'Drug Czar' Walks the Talk
Acting ‘Drug Czar’ Walks the Talk Navigate to the Next Story in this Section Botticelli: At D.C. drug-court graduation.(Anita Jarman, D.C. Courts) By Clara Ritger May 28, 2014 In front of a boisterous courtroom packed with recovering drug addicts and their family members sat an array of security guards and one neatly dressed White House official. Michael Botticelli, acting director of the Office of National Drug Control Policy, makes a habit of stopping by graduation ceremonies for the drug-court system—for both personal and professional reasons. The event last week in downtown Washington saw five people graduate from the city’s drug court, an alternative to the criminal-justice system that provides treatment for addicts and, in some cases—depending on state and local laws—allows them to return to society without a record provided they haven’t relapsed. Three of four drug-court graduates remain arrest-free for at least two years after leaving the program, according to the National Association of Drug Court Professionals. The drug-court system started about two decades ago, and already more than 2,700 drug courts are operating in the United States, according to the National Drug Court Institute. Botticelli was not completely out of place in the crowd; 26 years ago, at the age of 30, he was brought to court for drunken driving. He remembers the judge giving him two choices: Enter the criminal-justice system or get help for his alcohol addiction. He chose the latter. Botticelli’s experience led him to a lifetime of work helping people with substance-abuse problems. -
National Minority Quality Forum Announces 2021 Booker T. Washington Award Recipients
FOR IMMEDIATE RELEASE National Minority Quality Forum Announces 2021 Booker T. Washington Award Recipients WASHINGTON, D.C. (April 2, 2021)—Today, National Minority Quality Forum (NMQF) announced its 2021 Booker T. Washington Award recipients: ● BIO President Dr. Michelle McMurry-Heath ● Outstanding Non-Profit Award: Healthcare Ready ● Outstanding Corporate Citizen: Regeneron Pharmaceuticals The Booker T. Washington Award recognizes an individual or organization that has made an outstanding contribution to the promotion of wellness in emerging populations and is presented by NMQF. “The National Minority Quality Forum has had the honor of working with Dr. Michelle McMurry-Heath, Healthcare Ready, and Regeneron Pharmaceuticals—and we have seen the impact of their work. From breaking barriers as the first woman and African American to lead BIO; to advising on healthcare supply chain preparedness throughout the COVID-19 pandemic; to developing a novel treatment for COVID-19 and working to make it accessible to all, they have been equally committed to educating our communities on a variety of health issues. For all these reasons, we are honored that they are accepting the 2021 Booker T. Washington Award,” said NMQF’s President and CEO Dr. Gary Puckrein. “One of today’s leading social justice issues is greater and equitable access for all to the tremendous advances being made in science and medicine,” BIO President Dr. Michelle McMurry-Heath said. “Leaders in this effort stand on the shoulders of transformative advocates like Booker T. Washington, and I am deeply honored to accept this award as we strive to improve the health and welfare of Black Americans, vulnerable populations, and people everywhere.” Booker T. -
February 24, 2017 President Donald J. Trump the White House United States of America
February 24, 2017 President Donald J. Trump The White House United States of America Dear President Trump, Since the founding of this country, science has been fundamental to the advancement of sound policy and economic prosperity and innovation. Science improves the lives of Americans, stimulates our economy, advances our understanding of our world, and protects us and our families from harm. As you select advisors that will help you to draft a blueprint for American policy, we urge you to make appointing a Science Advisor an immediate priority. Science is in the DNA of the United States. It plays an integral part in our nation's security, economic growth, public health, and infrastructure. Appointing a Science Advisor quickly will enable the Administration to maximize investments in science and develop a strategic plan that secures America’s leadership in science. The Science Advisor will assist your administration in driving innovation, and provide scientifically sound solutions to the pressing issues facing our nation today; including updating deteriorating infrastructure, combatting health epidemics, providing clean air and water, and securing valuable natural resources and minerals. Appointing a Science Advisor is a smart investment for our nation and for keeping our position as a scientific leader globally. Due to the integral role of the Science Advisor, we urge you to appoint an individual with a strong scientific background who understands the rigorous scientific method, the need for evidence-based science, and who can leverage the collaborative nature of the scientific community and the value of scientific research in shaping America’s future. As supporters of science, we urge you to work with our scientific organizations as you commence the selection process and the important task of advancing America’s scientific enterprise. -
2020 International Narcotics Control Strategy Report
United States Department of State Bureau for International Narcotics and Law Enforcement Affairs International Narcotics Control Strategy Report Volume I Drug and Chemical Control March 2020 INCSR 2020 Volume 1 Table of Contents Table of Contents Common Abbreviations ..................................................................................................................................... iii International Agreements.................................................................................................................................... v INTRODUCTION ..................................................................................................................................... 1 Legislative Basis for the INCSR ......................................................................................................................... 2 Presidential Determination ................................................................................................................................. 7 Policy and Program Developments .................................................................................................... 12 Overview ......................................................................................................................................................... 13 Methodology for U.S. Government Estimates of Illegal Drug Production .......................................................... 18 Parties to UN Conventions .............................................................................................................................. -
Finland Country Drug Report 2017
Finland Country Drug Report 2017 Contents: At a glance | National drug strategy and coordination (p. 2) | Public expenditure (p. 3) | Drug laws and drug law offences (p. 4) | Drug use (p. 5) | Drug harms (p. 8) | Prevention (p. 10) | Harm reduction (p. 11) | Treatment (p. 12) | Drug use and responses in prison (p. 14) | Quality assurance (p. 15) | Drug-related research (p. 15) | Drug markets (p. 16) | Key drug statistics for Finland (p. 18) | EU Dashboard (p. 20) THE DRUG PROBLEM IN FINLAND AT A GLANCE Drug use Treatment entrants Overdose deaths Drug law offences in young adults (15-34 years) by primary drug in the last year 250 Cannabis 200 23 478 166 150 13.5 % Top 5 drugs seized 100 ranked according to quantities Cannabis, 21% 50 measured in kilograms Amphetamines, 15 % Cocaine, 0 % 0 1. Amphetamine 2011 2012 2013 2015 2014 Opioids, 52 % 2010 2007 2008 2006 9 % 17.9 % 2009 Other, 12 % 2. Herbal cannabis Other drugs Opioid substitution HIV diagnoses 3. Cannabis resin MDMA 2.5 % treatment clients attributed to injecting 4. Cocaine Amphetamines 2.4 % 14 5. Heroin Cocaine 1 % 12 3 000 10 Population 8 (15-64 years) 6 7 High-risk opioid users Syringes distributeddistributed 4 through specialised 2 3 483 757 programmes 0 13 836 2011 2012 2013 2015 2014 2010 2007 2008 2006 2009 Source: EUROSTAT (12 700 - 15 090) 5 301 000 Source: ECDC Extracted on: 26/03/2017 NB: Data presented here are either national estimates (prevalence of use, opioid drug users) or reported numbers through the EMCDDA indicators (treatment clients, syringes, deaths and HIV diagnosis, drug law offences and seizures). -
DEMAND REDUCTION a Glossary of Terms
UNITED NATIONS PUBLICATION Sales No. E.00.XI.9 ISBN: 92-1-148129-5 ACKNOWLEDGEMENTS This document was prepared by the: United Nations International Drug Control Programme (UNDCP), Vienna, Austria, in consultation with the Commonwealth of Health and Aged Care, Australia, and the informal international reference group. ii Contents Page Foreword . xi Demand reduction: A glossary of terms . 1 Abstinence . 1 Abuse . 1 Abuse liability . 2 Action research . 2 Addiction, addict . 2 Administration (method of) . 3 Adverse drug reaction . 4 Advice services . 4 Advocacy . 4 Agonist . 4 AIDS . 5 Al-Anon . 5 Alcohol . 5 Alcoholics Anonymous (AA) . 6 Alternatives to drug use . 6 Amfetamine . 6 Amotivational syndrome . 6 Amphetamine . 6 Amyl nitrate . 8 Analgesic . 8 iii Page Antagonist . 8 Anti-anxiety drug . 8 Antidepressant . 8 Backloading . 9 Bad trip . 9 Barbiturate . 9 Benzodiazepine . 10 Blood-borne virus . 10 Brief intervention . 11 Buprenorphine . 11 Caffeine . 12 Cannabis . 12 Chasing . 13 Cocaine . 13 Coca leaves . 14 Coca paste . 14 Cold turkey . 14 Community empowerment . 15 Co-morbidity . 15 Comprehensive Multidisciplinary Outline of Future Activities in Drug Abuse Control (CMO) . 15 Controlled substance . 15 Counselling and psychotherapy . 16 Court diversion . 16 Crash . 16 Cross-dependence . 17 Cross-tolerance . 17 Custody diversion . 17 Dance drug . 18 Decriminalization or depenalization . 18 Demand . 18 iv Page Demand reduction . 19 Dependence, dependence syndrome . 19 Dependence liability . 20 Depressant . 20 Designer drug . 20 Detoxification . 20 Diacetylmorphine/Diamorphine . 21 Diuretic . 21 Drug . 21 Drug abuse . 22 Drug abuse-related harm . 22 Drug abuse-related problem . 22 Drug policy . 23 Drug seeking . 23 Drug substitution . 23 Drug testing . 24 Drug use . -
Rethinking America's Illegal Drug Policy
NBER WORKING PAPER SERIES RETHINKING AMERICA'S ILLEGAL DRUG POLICY John J. Donohue III Benjamin Ewing David Peloquin Working Paper 16776 http://www.nber.org/papers/w16776 NATIONAL BUREAU OF ECONOMIC RESEARCH 1050 Massachusetts Avenue Cambridge, MA 02138 February 2011 The authors wish to thank Jonathan Caulkins, Phil Cook, Louis Kaplow, Rob MacCoun, Jeffrey Miron, Peter Reuter, and participants at two NBER conferences and the Harvard Law School Law and Economics workshop for valuable comments. We are also particularly grateful to Jeffrey Miron and Angela Dills for sharing their national time series data on drug prohibition enforcement and crime. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research. © 2011 by John J. Donohue III, Benjamin Ewing, and David Peloquin. All rights reserved. Short sections of text, not to exceed two paragraphs, may be quoted without explicit permission provided that full credit, including © notice, is given to the source. Rethinking America's Illegal Drug Policy John J. Donohue III, Benjamin Ewing, and David Peloquin NBER Working Paper No. 16776 February 2011, Revised March 2011 JEL No. K0 ABSTRACT This paper provides a critical review of the empirical and theoretical literatures on illegal drug policy, including cross-country comparisons, in order to evaluate three drug policy regimes: criminalization, legalization and “depenalization.” Drawing on the experiences of various states, as well as countries such as Portugal and the Netherlands, the paper attempts to identify cost-minimizing policies for marijuana and cocaine by assessing the differing ways in which the various drug regimes would likely change the magnitude and composition of the social costs of each drug.